Seres Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Seres Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2016 to Q3 2024.
  • Seres Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -816 %, a 83% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -816 +3.99K +83% Sep 30, 2024
Q2 2024 -772 -3.19K -132% Jun 30, 2024
Q1 2024 -1.62K -3.77K -175% Mar 31, 2024
Q4 2023 -1.75K -2.33K -397% Dec 31, 2023
Q3 2023 -4.81K -5.12K -1623% Sep 30, 2023
Q2 2023 2.42K +2.19K +966% Jun 30, 2023
Q1 2023 2.15K +1.97K +1134% Mar 31, 2023
Q4 2022 587 +447 +319% Dec 31, 2022
Q3 2022 316 +195 +161% Sep 30, 2022
Q2 2022 227 +117 +107% Jun 30, 2022
Q1 2022 174 +23.3 +15.5% Mar 31, 2022
Q4 2021 140 -146 -51% Dec 31, 2021
Q3 2021 121 -5.38K -97.8% Sep 30, 2021
Q2 2021 110 +435 Jun 30, 2021
Q1 2021 151 +571 Mar 31, 2021
Q4 2020 286 +689 Dec 31, 2020
Q3 2020 5.5K +5.89K Sep 30, 2020
Q2 2020 -325 +64.8 +16.6% Jun 30, 2020
Q1 2020 -420 -30.1 -7.72% Mar 31, 2020
Q4 2019 -403 +335 +45.4% Dec 31, 2019
Q3 2019 -396 -2.49K -119% Sep 30, 2019
Q2 2019 -390 -775 -201% Jun 30, 2019
Q1 2019 -390 -609 -279% Mar 31, 2019
Q4 2018 -738 -887 -593% Dec 31, 2018
Q3 2018 2.1K +1.97K +1556% Sep 30, 2018
Q2 2018 385 +273 +243% Jun 30, 2018
Q1 2018 218 +120 +122% Mar 31, 2018
Q4 2017 150 +63.1 +72.9% Dec 31, 2017
Q3 2017 127 +66.7 +112% Sep 30, 2017
Q2 2017 112 +75.3 +204% Jun 30, 2017
Q1 2017 98.3 +76.2 +345% Mar 31, 2017
Q4 2016 86.5 Dec 31, 2016
Q3 2016 59.8 Sep 30, 2016
Q2 2016 36.9 Jun 30, 2016
Q1 2016 22.1 Mar 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.